These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10387973)

  • 1. Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment.
    Robertson MJ; Ritz J
    Oncologist; 1996; 1(1 & 2):88-97. PubMed ID: 10387973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological properties and clinical significance of interleukins 12 (IL-12)].
    Marańda E; Robak T
    Postepy Hig Med Dosw; 1998; 52(5):489-506. PubMed ID: 9857673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
    Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
    Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
    Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
    J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination nonviral cytokine gene therapy for head and neck cancer.
    Li D; Zeiders JW; Liu S; Guo M; Xu Y; Bishop JS; O'Malley BW
    Laryngoscope; 2001 May; 111(5):815-20. PubMed ID: 11368072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro.
    Kelly-Rogers J; Madrigal-Estebas L; O'Connor T; Doherty DG
    Hum Immunol; 2006 Nov; 67(11):863-73. PubMed ID: 17145366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
    Eguchi J; Hiroishi K; Ishii S; Mitamura K
    Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
    Becker Y
    Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
    Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
    Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
    Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
    Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.